ATE374182T1 - Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose - Google Patents

Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose

Info

Publication number
ATE374182T1
ATE374182T1 AT01978757T AT01978757T ATE374182T1 AT E374182 T1 ATE374182 T1 AT E374182T1 AT 01978757 T AT01978757 T AT 01978757T AT 01978757 T AT01978757 T AT 01978757T AT E374182 T1 ATE374182 T1 AT E374182T1
Authority
AT
Austria
Prior art keywords
osteoporosis
receptor
treatment
selective agonists
agonists
Prior art date
Application number
AT01978757T
Other languages
English (en)
Inventor
K Keefe Cameron
Bruce A Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE374182T1 publication Critical patent/ATE374182T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01978757T 2000-11-27 2001-11-05 Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose ATE374182T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
ATE374182T1 true ATE374182T1 (de) 2007-10-15

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01978757T ATE374182T1 (de) 2000-11-27 2001-11-05 Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (de)
EP (1) EP1339678B1 (de)
JP (2) JP3984164B2 (de)
KR (1) KR20030053063A (de)
CN (1) CN1476429A (de)
AR (1) AR035074A1 (de)
AT (1) ATE374182T1 (de)
AU (1) AU2002210848A1 (de)
BG (1) BG107697A (de)
BR (1) BR0115687A (de)
CA (1) CA2429850C (de)
CY (1) CY1106976T1 (de)
CZ (1) CZ20031257A3 (de)
DE (1) DE60130675T2 (de)
DK (1) DK1339678T3 (de)
EA (1) EA200300379A1 (de)
EC (1) ECSP034623A (de)
EE (1) EE200300246A (de)
ES (1) ES2291361T3 (de)
GT (2) GT200100238A (de)
HN (1) HN2001000266A (de)
HU (1) HUP0400807A2 (de)
IL (1) IL155368A0 (de)
IS (1) IS6775A (de)
MA (1) MA26961A1 (de)
MX (1) MXPA03004623A (de)
NO (1) NO20032360L (de)
NZ (1) NZ525164A (de)
OA (1) OA12533A (de)
PA (1) PA8533901A1 (de)
PE (1) PE20020637A1 (de)
PL (1) PL362030A1 (de)
PT (1) PT1339678E (de)
SI (1) SI1339678T1 (de)
SK (1) SK5562003A3 (de)
SV (1) SV2003000746A (de)
TN (1) TNSN01166A1 (de)
TW (1) TW200424170A (de)
UY (1) UY27038A1 (de)
WO (1) WO2002042268A2 (de)
ZA (1) ZA200302803B (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339678B1 (de) * 2000-11-27 2007-09-26 Pfizer Products Inc. Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
MXPA04000454A (es) * 2001-07-16 2004-03-18 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanoides.
MXPA04000456A (es) * 2001-07-16 2004-03-18 Hoffmann La Roche Analogos de prostaglandina como agonistas del receptor ep4.
NZ530885A (en) 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
EP1481976B1 (de) 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
EP1490055A1 (de) * 2002-03-18 2004-12-29 Pfizer Products Inc. Verwendung von selektiven ep4 rezeptor-agonisten zur behandlung von leberinsuffizienz, verlust der durchgängigkeit des ductus arteriosus, glaukom oder okularer hypertonie
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
JP4766875B2 (ja) * 2002-06-06 2011-09-07 メルク フロスト カナダ リミテツド Ｅｐ４受容体作動薬、組成物及びその方法
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1556347A4 (de) * 2002-06-10 2006-08-09 Applied Research Systems Gamma-lactame als prostaglandinagonisten und deren verwendung
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. ８−アザプロスタグランジン誘導体およびその医薬用途
AU2004216857A1 (en) 2003-03-03 2004-09-16 Laboratoires Serono Sa G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
EP1654219A2 (de) 2003-07-18 2006-05-10 Applied Research Systems ARS Holding N.V. Hydrazinderivate als modulatoren des prostaglandinrezeptors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
CA2537119A1 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2537430A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN1845904A (zh) 2003-09-04 2006-10-11 默克公司 用于治疗高眼压的眼用组合物
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1696893A1 (de) * 2003-12-17 2006-09-06 Pfizer Products Incorporated Kontinuierliche kombinationstherapie mit selektivem prostaglandin-ep4, rezeptoragonisten und einem östrogen zur behandlung von erkrankungen mit geringer knochenmasse
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CA2574078A1 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
AU2005304764B2 (en) * 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
JP5014978B2 (ja) * 2005-01-27 2012-08-29 旭化成ファーマ株式会社 ヘテロ６員環化合物及びその用途
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (de) 2006-12-08 2020-02-05 University of Rochester Expansion hämatopoetischer stammzellen
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
CN102655859A (zh) 2009-10-14 2012-09-05 格穆斯药业股份有限公司 病毒感染的组合疗法治疗
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (de) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Verfahren zur Synthese von Beta-Aminosäuren und Derivaten daraus
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (de) 2012-02-16 2016-11-02 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP3175852B1 (de) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactamzusammensetzungen für ep4-vermittelte osteoverwandte erkrankungen und leiden
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
AU2014229065B2 (en) 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EP3235817B1 (de) * 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactamverbindungen als ep4-rezeptorselektive agonisten zur verwendung bei der behandlung von ep4-vermittelten erkrankungen und zuständen
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3152188B1 (de) 2014-06-06 2019-02-13 Allergan, Inc. Neuartige ep4-agonisten als therapeutische verbindungen
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
WO2016199111A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
ES3039622T3 (en) * 2016-03-04 2025-10-23 Univ Leland Stanford Junior Inhibitors of 15-hydroxyprostaglandin dehydrogenase for muscle regeneration
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
PH12020500556A1 (en) 2017-12-25 2021-04-19 Asahi Kasei Pharma Corp Nitrogen-containing six-membered ring compound
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (de) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
CA2346031A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
EP1148877A4 (de) 1998-10-15 2003-01-22 Merck & Co Inc Verfahren zur hemmung der knochenresorption
EA005293B1 (ru) * 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
EP1132086B1 (de) * 2000-01-31 2006-05-31 Pfizer Products Inc. Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
EP1339678B1 (de) * 2000-11-27 2007-09-26 Pfizer Products Inc. Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
KR20030053063A (ko) 2003-06-27
SK5562003A3 (en) 2004-08-03
US20030149086A1 (en) 2003-08-07
US7192979B2 (en) 2007-03-20
NO20032360D0 (no) 2003-05-26
ECSP034623A (es) 2003-07-25
BG107697A (en) 2004-01-30
HN2001000266A (es) 2002-01-30
TW200424170A (en) 2004-11-16
NZ525164A (en) 2005-04-29
CZ20031257A3 (cs) 2004-04-14
WO2002042268A2 (en) 2002-05-30
EE200300246A (et) 2003-10-15
JP2004521869A (ja) 2004-07-22
BR0115687A (pt) 2003-09-09
PT1339678E (pt) 2007-11-30
ZA200302803B (en) 2004-04-13
GT200100238A (es) 2002-06-26
JP2007197467A (ja) 2007-08-09
DE60130675T2 (de) 2008-01-24
AU2002210848A1 (en) 2002-06-03
WO2002042268A3 (en) 2002-07-25
SI1339678T1 (sl) 2007-12-31
US20020065308A1 (en) 2002-05-30
PE20020637A1 (es) 2002-07-18
JP3984164B2 (ja) 2007-10-03
EA200300379A1 (ru) 2003-08-28
TNSN01166A1 (fr) 2005-11-10
CA2429850A1 (en) 2002-05-30
NO20032360L (no) 2003-07-23
PA8533901A1 (es) 2002-11-28
CN1476429A (zh) 2004-02-18
MA26961A1 (fr) 2004-12-20
DE60130675D1 (de) 2007-11-08
OA12533A (en) 2006-06-05
PL362030A1 (en) 2004-10-18
US6552067B2 (en) 2003-04-22
IS6775A (is) 2003-04-10
DK1339678T3 (da) 2008-02-04
CA2429850C (en) 2008-12-30
EP1339678A2 (de) 2003-09-03
EP1339678B1 (de) 2007-09-26
MXPA03004623A (es) 2003-09-05
HUP0400807A2 (hu) 2004-07-28
AR035074A1 (es) 2004-04-14
GT200100238AA (es) 2004-05-12
SV2003000746A (es) 2003-01-13
IL155368A0 (en) 2003-11-23
CY1106976T1 (el) 2012-09-26
UY27038A1 (es) 2002-07-31
US20040259921A1 (en) 2004-12-23
US6747054B2 (en) 2004-06-08
ES2291361T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
DE60130675D1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE312117T1 (de) Verbindungen für die behandlung von ischämie
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
ATE420083T1 (de) Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE498309T1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
ATE276262T1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE60127712D1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE60006363D1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne
ATE271946T1 (de) Ausziehvorrichtung für pfannenspülsteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1339678

Country of ref document: EP

REN Ceased due to non-payment of the annual fee